Abstract
Eighty years ago Drury & Szent-Gyorgyi described the actions of adenosine, AMP (adenylic acid) and ATP (pyrophosphoric or diphosphoric ester of adenylic acid) on the mammalian cardiovascular system, skeletal muscle, intestinal and urinary systems. Since then considerable insight has been gleaned on the means by which these compounds act, not least of which in the distinction between the two broad classes of their respective receptors, with their many subtypes, and the ensuing diversity in cellular consequences their activation invokes. These myriad actions are of course predicated on the release of the purines into the extracellular milieu, but, surprisingly, there is still considerable ambiguity as to how this occurs in various physiological and pathophysiological conditions. In this review we summarise the release of ATP and adenosine during seizures and cerebral ischemia and discuss mechanisms by which the purines adenosine and ATP may be released from cells in the CNS under these conditions.
Current Neuropharmacology
Title: Release of Adenosine and ATP During Ischemia and Epilepsy
Volume: 7 Issue: 3
Author(s): Nicholas Dale and Bruno G. Frenguelli
Affiliation:
Abstract: Eighty years ago Drury & Szent-Gyorgyi described the actions of adenosine, AMP (adenylic acid) and ATP (pyrophosphoric or diphosphoric ester of adenylic acid) on the mammalian cardiovascular system, skeletal muscle, intestinal and urinary systems. Since then considerable insight has been gleaned on the means by which these compounds act, not least of which in the distinction between the two broad classes of their respective receptors, with their many subtypes, and the ensuing diversity in cellular consequences their activation invokes. These myriad actions are of course predicated on the release of the purines into the extracellular milieu, but, surprisingly, there is still considerable ambiguity as to how this occurs in various physiological and pathophysiological conditions. In this review we summarise the release of ATP and adenosine during seizures and cerebral ischemia and discuss mechanisms by which the purines adenosine and ATP may be released from cells in the CNS under these conditions.
Export Options
About this article
Cite this article as:
Dale Nicholas and Frenguelli G. Bruno, Release of Adenosine and ATP During Ischemia and Epilepsy, Current Neuropharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157015909789152146
DOI https://dx.doi.org/10.2174/157015909789152146 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic Basis of Sporadic Alzeimer’s Disease. Role of Hormones Related to Energy Metabolism
Current Pharmaceutical Design Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design ERRATUM 1
Current Neuropharmacology Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Sugar Sulfamates for Seizure Control: Discovery and Development of Topiramate, a Structurally Unique Antiepileptic Drug
Current Topics in Medicinal Chemistry Neuropeptide Y as an Endogenous Antiepileptic, Neuroprotective and Pro-Neurogenic Peptide
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Glutamate Receptors and Related Processes as Drug Targets (Guest Editor: Michel Baudry)]
Current Drug Targets On the Discovery and Development of CFTR Chloride Channel Activators
Current Pharmaceutical Design Effect of Dietary Supplementation of Black Seed (N. Sativa L.) on Lipid Profile of Patients Suffering from Diabetes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
CNS & Neurological Disorders - Drug Targets Activators and Inhibitors of the Ion Channel of the NMDA Receptor
Current Drug Targets Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Assessment of Possible Drug Interactions in Patients with Psoriasis and Associated Comorbid Medical Conditions: An Observational Study
Reviews on Recent Clinical Trials Antiepileptic Treatments in Developing Countries
Current Pharmaceutical Design Impact of Novel Screening Technologies on Ion Channel Drug Discovery
Combinatorial Chemistry & High Throughput Screening Ester Prodrugs of Ketoprofen: Synthesis, In Vitro Stability, In Vivo Biological Evaluation and In Silico Comparative Docking Studies Against COX-1 and COX-2
Current Drug Discovery Technologies Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Mobilization and Redistribution of Default Mode Network from Resting State to Task State in Amnestic Mild Cognitive Impairment
Current Alzheimer Research